ClinicalTrials.gg
RecruitingNCT05103683Updated Feb 13, 2026

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

A Phase 1 interventional study of TORL-1-23 in Advanced Solid Tumor, Ovarian Cancer and Endometrial Cancer, sponsored by TORL Biotherapeutics, LLC. Recruiting at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by TORL Biotherapeutics, LLC · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,779 studies in Ovarian Neoplasms with a site in United States — 278 open to participants now, 454 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
477th of 1,498
90 · median 47
Started
2021
with 95 others
Phase 1
547 of 1,779
73 open now
Primary completion
2026-08
later than 89 of 452 live
Registered
1,414th of 1,779
by date

Among the 1,779 studies in Ovarian Neoplasms with a site in United States, this one is the 477th largest by planned enrollment of the 1,498 interventional ones that give a count, is one of 96 that started in 2021, is one of 547 in phase 1, reaches primary completion later than 89 of the 452 other live ones, and was the 1,414th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

278 of the 1,779 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

273 more — sign in →

All 278 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,779 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

03

Conditions studied

  • Advanced Solid Tumor
  • Ovarian Cancer
  • Endometrial Cancer
  • NSCLC

Keywords

  • claudin6
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced solid tumor
  • , per v1.1
  • (ECOG) performance status 0-1
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has not recovered [recovery is defined as , version 5.0, grade ≤1] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements
  • Received prior chemotherapeutic, , or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-1-23
  • Progressive or symptomatic
  • Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
  • History of significant cardiac disease
  • History of myelodysplastic syndrome (MDS) or AML
  • History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded
  • If female, is pregnant or breastfeeding
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Monotherapy Dose Finding - Part 1

    TORL-1-23

    Drug: TORL-1-23

  • Experimental
    Expansion as Monotherapy - Part 2

    TORL-1-23

    Drug: TORL-1-23

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events and serious adverse events

    Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0

    Time frame: up to 2 years

  2. Maximum Tolerated Dose (MTD)

    Highest administered dose with \< 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants

    Time frame: 28 Days

  3. Recommended Phase 2 Dose (RP2D)

    Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data

    Time frame: up to 2 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    Percentage of participants with best response of complete response (CR) or partial response (PR) according to RECIST 1.1

    Time frame: up to 2 years

  2. Duration of Response (DOR)

    Time from CR or PR to objective disease progression or death to any cause

    Time frame: up to 2 years

  3. Progression Free Survival (PFS)

    PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause

    Time frame: up to 2 years

  4. Time to Response (TTR)

    Time from start of treatment to complete response or partial response

    Time frame: up to 2 years

  5. 1 Year Overall Survival (1YOS)

    Proportion of participants alive at 1 year from the start of treatment to death from any cause

    Time frame: 1 year

  6. 2 Year Overall Survival (2YOS)

    Proportion of participants alive at 2 years from the start of treatment to death from any cause

    Time frame: 2 years

  7. Number of anti-drug antibody (ADA) Positive Participants

    Immunogenicity will be measured by the number of participants that are ADA positive.

    Time frame: up to 2 years

  8. Maximum Serum Concentration of TORL-1-23 (Cmax)

    PK assessment

    Time frame: 21 days

  9. Minimum Serum Concentration of TORL-1-23 (Cmin)

    PK assessment

    Time frame: 21 days

  10. Maximum Serum Concentration of TORL-1-23 at Steady State (Cmax,ss)

    PK assessment

    Time frame: 63 days

  11. Minimum Serum Concentration of TORL-1-23 at Steady State (Cmin,ss)

    PK assessment

    Time frame: 63 days

  12. Time of Maximum Serum Concentration of TORL-1-23 (Tmax)

    PK assessment

    Time frame: 21 days

  13. Time of Minimum Serum Concentration of TORL-1-23 (Tmin)

    PK Assessment

    Time frame: 21 days

  14. Time of Minimum Serum Concentration of TORL-1-23 at Steady State (Tmin,ss)

    PK Assessment

    Time frame: 63 days

  15. Terminal Half-life (t1/2) of Serum TORL-1-23

    PK Assessment

    Time frame: 63 days

  16. Area under the Serum Concentration-Time curve from the time of dosing to the last measurable concentration (AUClast) for TORL-1-23

    PK Assessment

    Time frame: 21 days

  17. Area under the Serum Concentration-Time curve from the time of dosing extrapolated to time infinity (AUCinf) for TORL-1-23

    PK Assessment

    Time frame: 63 days

  18. Apparent volume of distribution during the terminal phase (Vz) of TORL-1-23

    PK Assessment

    Time frame: 63 days

  19. Clearance (CL) of TORL-1-23

    PK Assessment

    Time frame: 63 days

  20. Accumulation ratio (Rac) of TORL-1-23

    PK Assessment

    Time frame: 63 days

07

Study locations

14 of 14 sites recruiting
  • Providence Medical Foundation
    Fullerton, California 92835, United States
    Recruiting
    • Yung Lyou, MD · Contact
  • UCLA - JCCC Clinical Research Unit
    Los Angeles, California 90095, United States
    Recruiting
    • Gottfried Konecny, MD · Contact310-794-4955
    • Gottfired Konecny, MD · Principal investigator
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
    Recruiting
    • John Villano, MD · Contact
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
    Recruiting
    • Boris Winterhoff, MD, PhD · Contact612-624-8003
    • Boris Winterhoff, MD, PhD · Principal investigator
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
    • Andrea Wahner Hendrickson, MD · Contact855-776-0015
    • Andrea Wahner Hendrickson, MD · Principal investigator
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Emily Slotkin, MD · Contact
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • Alex Adjei, MD · Contact
  • Sarah Cannon Research Institute Texas Oncology
    Tyler, Texas 75702, United States
    Recruiting
    • Heather Pulaski, MD · Contact
    • Heather Pulaski, MD · Principal investigator
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
    Recruiting
    • Alexander Spira, MD · Contact
  • St. Vincent's Hospital, The Catholic University of Korea
    Suwon, Gyeonggi-do 16247, South Korea
    Recruiting
    • Byoung Yong Shim, MD · Contact
    • Byoung Yong Shim, MD · Principal investigator
  • Seoul National University Hospital
    Seoul, 03080, South Korea
    Recruiting
    • Bhumsuk Keam, MD · Contact
    • Bhumsuk Keam, MD · Principal investigator
  • Severance Hospital
    Seoul, 03723, South Korea
    Recruiting
    • Gun Min Kim, MD · Contact
    • Gun Min Kim, MD · Principal investigator
  • Asan Medical Center
    Seoul, 05505, South Korea
    Recruiting
    • Shinkyo Yoon, MD · Contact
    • Shinkyo Yoon, MD · Principal investigator
  • Samsung Medical Center
    Seoul, 06351, South Korea
    Recruiting
    • Jinseok Ahn, MD · Contact
    • Jinseok Ahn, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Aug 2026, 57 months after the start.

Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 57 months is above that.

Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2021
First posted
Nov 2, 2021
StartActual
Nov 17, 2021
Primary completionEst.
Aug 31, 2026
CompletionEst.
Nov 15, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05103683
Lead sponsor
TORL Biotherapeutics, LLC
Collaborators
Translational Research in Oncology
Responsible party
Sponsor
First posted
Nov 2, 2021
Start date
Nov 17, 2021
Primary completion
Aug 31, 2026 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Feb 13, 2026

Study contacts

Nora Ku, MD
Contact
nora.ku@torlbio.com
310-348-9636
Ibrahim Qazi
Contact
310-348-9636
Nora Ku, MD
study chair · TORL Biotherapeutics, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixotatug vedotin

Start the discussion